Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Please provide your email address to receive an email when new articles are posted on . Adding immune checkpoint inhibitors to neoadjuvant chemotherapy benefited certain patients with early-stage ...

Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, ...

USA: A matched-cohort study found that patients with lung cancer, melanoma, or kidney cancer who received PCSK9 inhibitors ...

Patients with advanced squamous non-small-cell lung cancer who received the bispecific antibody ivonescimab alongside ...

ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...

The trial is active in Europe and Asia across 44 sites in six countries and now includes two in the US.

Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDAPotential breakthrough therapy ...